MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...
JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...
The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for ...
Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...
Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at the 2026 AD/PD™ Conference· Data evaluated safety, tolerability, ...
The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...
Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 ...
Lundbeck to present phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease at the 2026 AD/PD conference: Valby, Denmark Tuesday, ...
Citius Oncology reports positive results from phase 1 study of Lymphir in combo with pembrolizumab in relapsed or refractory gynaecologic cancers: Cranford, New Jersey Friday, Mar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results